- Home
- ASA vs VRDN Comparison
ASA vs VRDN Comparison
Compare ASA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASA | VRDN |
|---|---|---|
| Founded | 1958 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASA | VRDN |
|---|---|---|
| Price | $69.78 | $17.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $35.46 |
| AVG Volume (30 Days) | 48.8K | ★ 2.9M |
| Earning Date | 06-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | N/A | $279.00 |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.67 | $12.48 |
| 52 Week High | $83.20 | $34.29 |
Technical Indicators
Market Signals| Indicator | ASA | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 54.63 |
| Support Level | $65.80 | $15.68 |
| Resistance Level | $72.77 | $19.54 |
| Average True Range (ATR) | 2.52 | 0.86 |
| MACD | 0.58 | 0.72 |
| Stochastic Oscillator | 78.07 | 66.57 |
Price Performance
Historical ComparisonAbout ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.